[go: up one dir, main page]

WO2005084364A3 - Long acting tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs - Google Patents

Long acting tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs Download PDF

Info

Publication number
WO2005084364A3
WO2005084364A3 PCT/US2005/006941 US2005006941W WO2005084364A3 WO 2005084364 A3 WO2005084364 A3 WO 2005084364A3 US 2005006941 W US2005006941 W US 2005006941W WO 2005084364 A3 WO2005084364 A3 WO 2005084364A3
Authority
WO
WIPO (PCT)
Prior art keywords
long acting
tissue protective
restoration
organs
enhancement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/006941
Other languages
French (fr)
Other versions
WO2005084364A2 (en
Inventor
Michael Brines
Anthony Cerami
Carla Hand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warren Kenneth S Institute Inc
Original Assignee
Warren Kenneth S Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warren Kenneth S Institute Inc filed Critical Warren Kenneth S Institute Inc
Publication of WO2005084364A2 publication Critical patent/WO2005084364A2/en
Publication of WO2005084364A3 publication Critical patent/WO2005084364A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Methods and compositions are provided for protecting or enhancing a responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of a long acting tissue protective cytokine. In particular, the long acting tissue protective cytokines of the present invention relate to modified long acting erythropoietins exhibiting a tissue protective effect without an erythropoietic related activity.
PCT/US2005/006941 2004-03-03 2005-03-03 Long acting tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs Ceased WO2005084364A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54967504P 2004-03-03 2004-03-03
US60/549,675 2004-03-03

Publications (2)

Publication Number Publication Date
WO2005084364A2 WO2005084364A2 (en) 2005-09-15
WO2005084364A3 true WO2005084364A3 (en) 2006-03-02

Family

ID=34919524

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/006941 Ceased WO2005084364A2 (en) 2004-03-03 2005-03-03 Long acting tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs

Country Status (1)

Country Link
WO (1) WO2005084364A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
GB0525540D0 (en) * 2005-12-15 2006-01-25 Isis Innovation New treatment
EP2303309A2 (en) * 2008-05-22 2011-04-06 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604198A (en) * 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US20030077753A1 (en) * 2001-09-25 2003-04-24 Wilhelm Tischer Diglycosylated erythropoietin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5604198A (en) * 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US20030077753A1 (en) * 2001-09-25 2003-04-24 Wilhelm Tischer Diglycosylated erythropoietin

Also Published As

Publication number Publication date
WO2005084364A2 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
PL377146A1 (en) Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
WO2004003176A3 (en) Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
WO2002053580A3 (en) Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
EA200600076A1 (en) COMPOSITIONS AND METHODS OF INCREASING THE ACTIVITY OF TELOMERASE
WO2004101758A3 (en) Composition for maintaining organ and cell viability
IL164079A0 (en) Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
PT1404811E (en) CARBON MONOXIDE IMPROVES RESULTS IN TISSUE AND ORGAN TRANSPLANTS AND DELETERS APOPTOSIS
WO2005030083A3 (en) Methods and products which utilize n-acyl-l-aspartic acid
WO2005032494A3 (en) Lpa receptor agonists and antagonists and methods of use
WO2007037653A8 (en) Use of mesenchymal stem cells genetically modified to express a suicide gene for treating a cancer
NO20056000L (en) Tissue-protecting cytokines for the protection, reconstruction and enhancement of responsive cells, tissues and organs with an expanded therapeutic window
PL377205A1 (en) Use of active extracts to improve the appearance of skin, lips, hair and/or nails
EP1962843A4 (en) USE OF PARP-1 INHIBITORS
WO2007025166A3 (en) Devices, compositions and methods for the protection and repair of cells and tissues
WO2005084364A3 (en) Long acting tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
WO2004043346A3 (en) Compositions containing an active fraction isolated from lycium barbarum and methods of using the same
EP1478660A4 (en) KAPPA-PVIIA-RELATED CONOTOXINES AS MEANS FOR THE PROTECTION OF ORGANS
WO2024173520A3 (en) Rnai agents for inhibiting expression of thymic stromal lymphopoietin (tslp), compositions thereof, and methods of use
TW200616655A (en) Pharmaceutical use of graptopetalum and related plants
NO20062506L (en) Tissue-protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues, and organs with an extended therapeutic window
WO2007055760A3 (en) Protein composition for promoting wound healing and skin regeneration
WO2006000923A3 (en) Macrolide compositions as therapeutic agent
WO2007022140A3 (en) Methods of improving cardiac function and attenuating and/or preventing cardiac remodeling with hsp20
WO2007110704A3 (en) Macrolide compositions as therapeutic agent
WO2002059279A3 (en) Preparation of replicating kupffer cells and their use in diagnosis and therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase